

ORIGINAL ARTICLE



OPEN ACCESS OPEN ACCESS

Mortality of neurological disorders in Tanzania: analysis of baseline data from sample vital registration with verbal autopsy (SAVVY)

Francis Levira^{a,b,c}, Charles R. Newton^{d,e}, Honorati Masanja^c and Peter Odermatt^{a,b}

^aDepartment of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; ^bUniversity of Basel, Basel, Switzerland; ^cHealth Systems, Impact Evaluation, and Policy, Ifakara Health Institute, Dar-es-Salaam, Tanzania; ^dKenya Medical Research Programme-Wellcome Trust Collaborative Programme, Kilifi, Kenya; ^eDepartment of Psychiatry, University of Oxford, Oxford, UK

ABSTRACT

Background: Neurological disorders (ND) have a profound consequence on human productivity, quality of life and survival. There are limited data on the burden of ND in Tanzania due to insufficient coverage of civil and vital registration systems.

Objectives: This study was conducted to estimate mortality of ND in all ages in Tanzania using data from the Sample Vital Registration with Verbal Autopsy (SAVVY) study.

Methods: Multistage random sampling was employed to select 23 districts, 1397 census enumeration areas and 154,603 households. During the baseline survey conducted between 2011 and 2014, deaths which occurred 12 months prior to the baseline survey were documented followed by verbal autopsy interviews. Causes of death were certified using International Classification of Diseases.

Results: The baseline survey enrolled a total of 650,864 residents. A total of 6645 deaths were reported to have occurred 12 months before the date of survey. Death certification was available for 5225 (79%) deaths. The leading causes of death were cerebrovascular diseases with a cause-specific mortality fraction (CSMF) of 1.64% (95% Cl: 1.30–1.99) and 3.82% (95% Cl: 2.92–4.72) in all ages and adults older than 50 years, respectively. Stroke accounted for 92% of all cerebrovascular deaths. Mortality of epilepsy was estimated with a CSMF of 0.94% (95% Cl: 0.68–1.20); meningitis with a CSMF of 0.80% (95% Cl: 0.56–1.04); cerebral palsy and other paralytic syndromes with a CSMF of 0.46% (95% Cl: 0.27–0.65); and intrauterine hypoxia in neonates with a CSMF of 2.06% (95% Cl: 1.12–3.01). Overall, mortality of ND was estimated with a CSMF of 4.99% (95% Cl: 4.40–5.58).

Conclusions: The SAVVY survey provides estimates of mortality burden of ND in Tanzania. The study provides a basis for monitoring trends of ND and contributes to advancing knowledge of the burden of diseases. Integrating morbidities measures into the SAVVY design will provide comprehensive measures of burden of ND taking into account lifetime disabilities created by ND.

ARTICLE HISTORY

Received 5 June 2018 Accepted 6 February 2019

RESPONSIBLE EDITOR Stig Wall, Umeå University, Sweden

KEYWORDS

Cerebrovascular; epilepsy; meningitis; cerebral palsy; intrauterine hypoxia

Background

Neurological disorders (ND) have a profound consequence on human productivity, quality of life and survival in developed and developing countries. The most prevalent ND globally include dementia (progressive memory loss); Parkinson's (impaired motor system); multiple sclerosis (problem with vision, movement, sensation or balance); epilepsy (sudden recurrence of unprovoked seizures); and stroke (two or one sides paralysis or numbness).

Dementia and Parkinson's disease are the most common ND in most developed countries with a reported increasing trend [1]. The increases in ND's mortality in developed countries are higher than increases in other chronic diseases such as cancer and diseases of circulation [2]. Substantial proportions of neurological disorders in developed countries are thought to be attributed to increased life expectancy (aging) and unhealthy lifestyle [3].

In most developing countries, on the other hand, etiological studies reported that most ND originate from infections of the central nervous system (CNS) and brain trauma [4–7]. The most common reported ND in sub-Saharan Africa (SSA) include stroke, epilepsy, meningitis, paraparesis, neuropathies, and traumatic brain injuries [8–10].

In 2010, Global Burden of Disease (GBD) report indicated that non-communicable diseases (NCD) accounted for 54% of global burden of disease (morbidities and premature mortality); an increase from 43% in 1990 [11]. With the rapid epidemiological transition in developing countries, mortalities associated with age-related and lifestyle ND are expected to increase in the presence of infection-related ND; therefore, deliberate efforts in understanding the epidemiology of ND is necessary.

CONTACT Francis Levira Stevira flevira@ihi.or.tz B Ifakara Health Institute, PO Box 78373, Dar es Salaam, Tanzania © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The morbidity and mortality burden of stroke as an example is reported to increase in developing countries, accounting for 75% of global deaths and 81% stroke-related Disability Adjusted Life Years (DALYs) [12].

In SSA, there is a paucity of national data on the epidemiology of ND. Most references of national estimates of the burden of NDs are cited from the modeled estimates of GBD study. However, for most developing countries, input parameters used in modeling are obtained from inadequate vital registrations records or small local studies. Coverage of mortality and morbidity for China and India as an illustration was only 15% and 1%, respectively, for mental, neurological and substance abuse at the time GBD for the year 2013 was estimated [13]. Model-based estimates from GBD not only are free from coverage limitations but also considerable reliance on geospatial data and experts' opinions [12]. Global estimates in some countries and cases deviate from the true epidemiological profile and thus are deemed unreliable for local planning by policy makers [14].

Tanzania lacks national mortality data on ND due to the insufficient coverage of civil and vital registration systems as in many SSA countries [15,16]. Poor coverage of civil and vital registration systems at a national level and over-reliance on global estimation have concealed crucial statistics necessary in understanding population health, improving health outcomes and monitoring disease trends [17,18]. Several studies have linked higher coverage of civil and vital statistics with improved health outcomes in several countries [18].

In an effort to increase utilization of local data for comprehensive health planning, the Tanzanian government was supported by development partners to develop and implement a SAmple Vital registration with Verbal AutopsY (SAVVY) study aimed at providing nationally representative estimates of mortality and causes of death by sex, residence, and zone [19]. Nearly 75% of deaths occur at home in most developing countries and cause of death determination is nearly absent in Tanzania as it is in many low- and middle-income countries. Alternatively, the verbal autopsy (VA) process facilitates generation of causes of death statistics in situations where post-mortem examinations and death certification are not routinely conducted [20-22]. VA remained the only tool reliable for providing vital statistics information.

We examined the SAVVY data to estimate mortality rates of the neurological disorders by sex, age, residence, and zones in Tanzania.

Material and methods

Design and sampling

SAVVY is a community-based system implemented in a nationally representative cluster sample [19]. Multistage random sampling was employed to select 23 districts, 1397 enumeration areas, and 154,603 households from mainland Tanzania, stratified by residency and zones to meet the proposed overall sample. The sampling frame for this study was based on the 2002 Population and Housing Census for Tanzania Mainland. A full description of design and methods has been published elsewhere [23]. Figure 1 shows the map of Tanzania with shaded sampled districts.

Baseline census

Baseline censuses were sequentially conducted in 23 districts between 2011 and 2014 in order to establish denominators for estimating different demographic indicators. During the baseline census, the sociode-mographic information of the household members was collected which included: age, sex, education, and relationship to head of household. Deaths that had occurred during the 12 months prior to the census date were retrospectively documented in all households.

Verbal autopsy

Verbal autopsy (VA) interviews were conducted for all documented deaths by trained SAVVY VA coordinators with the most appropriate person in the household after setting up an appointment. Standard verbal autopsy questionnaires (2007 version) that have been developed by the World Health Organization (WHO) in collaboration with other stakeholders were used [24]. Completed VA questionnaires were sent to physicians for a cause of death certification.

Physician's assignment of causes of deaths

The cause of death for each interviewed death was determined using the International Classification of Diseases, tenth revision (ICD-10), as published by the WHO [25]. Each VA questionnaire of the deceased was reviewed independently by two physicians to ascertain causes of deaths and produce death certificates. In case of discrepancies, two independent physicians met to resolve the discrepancies. If disagreed, the cause of death was declared undetermined (meaning there was no sufficient information to determine the cause of death). Physicians reviewing VA questionnaires were medical doctors (not neurologists) independent of the research institution trained on death certification using ICD-10 classification.

Death certificates were requested and documented during VA interviews. However, these certificates were rarely available and coded in ICD-10; therefore, for consistency reasons, we did not consider these



Figure 1. Geographic locations of 23 SAVVY districts on a map of Tanzania.

certificates. Neurological causes of deaths were classified using code ranges of G00–G99 for diseases of nervous system, I60–69 for cerebrovascular diseases, P20 for intrauterine hypoxia, C71 for malignant neoplasm of brain, D33 for benign neoplasm of brain and other parts of the CNS, Q00–Q07 for congenital malformations of the nervous system, S06 for traumatic brain injuries/intracranial injury, and R25–R29 for symptoms and signs involving the nervous and musculoskeletal systems [26,27].

Statistical analysis

National Population and Housing Census data were used to provide a basis for data weighting. The gross weight was estimated as the product of reciprocal of the probability of selection of districts within zones, enumeration area (EA) within districts and households within EA. Mortality rate was estimated as a weighted ratio of the number of deaths and population. Cause-specific mortality fraction (CSMF) was calculated as a ratio of deaths due to a specific cause over the total number of deaths for which cause of death information was available. CSMF were compared across the subpopulation by calculating the mortality rate fraction (MRF), which is the ratio of two CSMF. Females, urban, and age 50 and above and lake zone were set as the reference category for CSMF comparisons. Lake zone is known to have poor intervention coverage for a substantial number of health systems performance indicators; therefore, we set it as a reference category [28].

Results

A total of 650,864 residents in 154,603 households were enrolled during the baseline census survey. There were 91,329 (51%) households in rural areas and 63,274 (41%) in urban areas. The majority of households were headed by males (72%). The average household size was 4.5 in rural areas and 3.7 in urban areas. A total of 6645 deaths were documented to have occurred 12 months prior to the baseline survey corresponding to an annual weighted crude death rate of 10.8 (95% CI: 10.8–10.9) deaths per 1000 population. Teh age distribution of the reported deaths is shown in death pyramid in Figure 2.

VA interviews were conducted for 6608 (99%) of the documented 6645 deaths. Causes of death certification were completed for 5225 (79%) of 6608 VA interviewed deaths. Of 5225 deaths with complete cause of death, 872 (17%) were newborn aged 0–29 days (VA form 1), 1096 (21%) were children aged 29 days–14 years (VA form 2) and 3257 (62%) were adults older than 15 years (VA form 3). Causes of death could not be ascertained for 1383 deaths due to absence of a reliable caregiver to respond to the VA interview, incomplete VA interviews, and incomplete cause of death determination by physicians, among other things.

Causes of neurological deaths

A total of 261 neurological deaths were determined; 72 (27.6%) were children younger than 5 years, 22 (8.4%) were children aged 5–19 years, 65 (24.9%) were adults aged 20–49 years, and 102 (39.1%) were adults older



Figure 2. Age distribution of 6645 reported deaths (3509 males and 3136 females) from SAVVY districts.

than 50 years. All neurological deaths were coded into 30 three- or four-digit ICD-10 causes and later grouped into nine major categories of cerebrovascular diseases, meningitis, epilepsy, cerebral palsy and other paralytic syndromes, intrauterine hypoxia, malignant and benign neoplasms of brain and CNS, congenital malformations of the nervous system, other neurological disorders, and symptoms and signs involving the nervous and musculoskeletal systems (Table 1).

Neurological disorders mortality

Of the reported ND-related deaths, the leading causes were cerebrovascular diseases (33.0%), epilepsy (18.4%), meningitis (16.1%), cerebral palsy and other paralytic syndromes (CP) (9.2%), and intrauterine hypoxia (IH) (6.9%). All causes mortality of ND was estimated with a CSMF of 4.99% (95% CI: 4.40-5.59) (Table 2). There were no differences in CSMF among males (4.76%) and females (5.27%) (MRF = 0.90, 95% CI: 0.70-1.16). Compared to adults aged 50 years and above, mortality of ND was estimated to be lower among children aged 0-4 (MRF = 0.71, 95% CI: 0.52-0.97), and comparable in children aged 5-19 (MRF = 1.07, 95% CI: 0.64-1.72) and adults aged 20-49 (MRF = 1.07, 95% CI: 0.64-1.72). Mortality was lower by 23.0% in urban (4.35%) than rural (5.63%) areas (MRF = 0.77, 95% CI: 0.40-0.99). Mortality of ND was comparable across zones. Using census population and crude death rate of 2012 and CSMF observed in this study, we estimated the number of neurological deaths to range from 18,000 to 22,000 in Tanzania in 2012.

Cerebrovascular mortality

Cerebrovascular diseases are a category of a broader group of diseases of the circulatory system.

Cerebrovascular diseases accounted for 19.0% of all deaths from diseases of circulation, after hypertension which accounted for 66.0% of deaths from diseases of circulation. A total of 86 cerebrovascular deaths were reported out of 5225 certified deaths. Among those who died of cerebrovascular diseases, stroke was the leading cause of death, constituting 92.0% of all reported cerebrovascular deaths. The remaining 8.0% constituted hypertensive encephalopathy, sequelae of stroke not specified as hemorrhage or infarction. and sequelae of other unspecified cerebrovascular diseases.

The mortality of cerebrovascular-related deaths was estimated with a CSMF of 1.64% (95% CI: 1.30-1.99); with a higher estimate in adults older than 50 years (3.82%) than adults aged 20-49 (1.31%) (MRF = 3.4, 95% CI: 1.19-5.58) (Table 2). There was a comparable estimate in urban (1.98%) and rural (1.32%) populations (MRF = 1.5, 95% CI: 0.95-2.37). No significant differences were observed between lake zone and other zones.

In adults older than 50 years, the mortality of cerebrovascular-related deaths was estimated with a CSMF of 3.82% (95% CI: 2.92–4.72). CSMF was lower in males (2.87%) than females (4.93%) (MRF = 0.58, 95% CI: 0.34–0.97), comparable in urban (4.19%) and rural (3.42%) (MRF = 1.23, 95% CI: 0.73–2.06), and lower in central zone (1.68%) compared to lake zone (6.22%) (MRF = 0.27, 95% CI: 0.08–0.76).

Epilepsy mortality

Of all ND-related deaths, epilepsy accounted for 18.4%; 4.2% among children < 5 years, 40.9% among children aged 5–19, 36.9% among adults aged 20–49, and 11.8% among adults older than 50 years (Table 1). Unspecified convulsive epilepsy (98.0%) and other generalized Table 1. Distribution of causes of neurological death by age group.

<5		Age group				
Cerebrovascular diseases 1.4 27.7 65.7 33.0 Stroke, not specified as hemorrhage or infarction 1.4 24.6 60.8 30.3 Sequelae of stroke, not specified as hemorrhage or infarction 3.1 2.9 1.9 Sequelae of other and unspecified cerebroxacular diseases 1.0 0.4 Epilepsy 4.2 40.9 36.9 11.8 88.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 42 22.7 10.8 4.9 14.6 Cerebral palsy unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy unspecified 8.3 13.6 35.0 35.0 35.0 Paralytic syndrome, unspecified 8.3 13.6 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0		<5	5–19	20–49	50+	All ages
Stroke, not specified as hemorrhage or infarction 1.4 24.6 60.8 30.3 Sequelae of stroke, not specified as hemorrhage or infarction 3.1 2.9 1.9 Sequelae of other and unspecified cerebrovascular diseases 1.0 0.4 Epilepsy 4.2 40.9 36.9 11.8 88.4 Other generalized epilepsy and epileptic syndromes 1.0 0.4 Epilepsy. unspecified 4.2 40.9 36.9 11.8 88.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Scretral palsy and other paralytic syndromes 1.1 18.2 4.9 14 0.4 Cerebral palsy unspecified 29.2 22.7 10.8 4.9 14.8 Cerebral palsy, unspecified 4.4 1.5 2.0 1.5 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauetine hypoxia 2.5 1.5 0.4 1.5 2.0 1.5 Intrauetine hypoxia 2.5 1.5 0.4 0.4 <td>Cerebrovascular diseases</td> <td>1.4</td> <td></td> <td>27.7</td> <td>65.7</td> <td>33.0</td>	Cerebrovascular diseases	1.4		27.7	65.7	33.0
Hypertensive encephalopathy 1.0 0.4 Sequelae of stoke, not specified as hemorhage or infarction 3.1 2.9 1.9 Sequelae of other and unspecified cerebrovascular diseases 1.0 0.4 Epilepsy 4.2 40.9 36.9 11.8 18.4 Epilepsy, unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 4.2 4.2 40.9 36.9 11.8 18.4 Meningitis, unspecified 4.2 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 4.2 22.7 10.8 4.9 14. Cerebral palsy 1.4 .0.4 .0.4 .0.4 .0.4 Cerebral palsy, unspecified 8.3 13.6 .0.4 .0.4 .0.4 Paralpeigia, unspecified 1.4 1.5 2.0 1.5 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4 .0.4	Stroke, not specified as hemorrhage or infarction	1.4		24.6	60.8	30.3
Sequelae of stroke, not specified as hemorrhage or infarction 3.1 2.9 1.9 Sequelae of other and unspecified cerebrovascular diseases 1.0 0.4 Epilepsy 4.2 40.9 36.9 11.8 18.4 Other generalized epilepsy and epileptic syndromes 1.0 0.4 Epilepsy. unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, out elsewhere classified 4.2 0.8 9.9 14.8 Cerebral palsy and other paralytic syndromes 1.1 18.2 3.1 9.8 9.2 Cerebral palsy, unspecified 1.4 5.1 9.8 9.2 1.9 Cerebral palsy, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 1.5 1.5 1.5 Malignant neoplasm of brain 3.1 1.0 1.9 Malignant neoplasm of brain and CNS 9.1 3.1 1.0 1.9 Congenital mafformatio	Hypertensive encephalopathy				1.0	0.4
Sequelae of other and unspecified cerebrovascular diseases 1.0 0.4 Epilepsy 36.9 11.8 18.4 Other generalized epilepsy and epileptic syndromes 1.0 0.4 Epilepsy, unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy 1.4 0.4 0.4 0.4 Cerebral palsy, unspecified 8.3 13.6 3.5 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paraplegia, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 3.1 0.8 0.4 1.9 Paraplegia, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 3.1 0.8 0.4 0.4 Corebral palsy 1.4 1.5 0.4 0.4 Corebral palsy 1.6 1.5 2.0 1.5 1.5	Sequelae of stroke, not specified as hemorrhage or infarction			3.1	2.9	1.9
Epilepsy 4.2 40.9 36.9 11.8 18.4 Other generalized epilepsy and epileptic syndromes 1.0 0.4 Epilepsy, unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy 1.4 0.4 0.4 0.4 0.4 Cerebral palsy, unspecified 29.2 22.7 10.8 4.9 14.6 0.4 Cerebral palsy, unspecified 1.4 0.4 9.8 9.2 1.9 9.1	Sequelae of other and unspecified cerebrovascular diseases				1.0	0.4
Other generalized epilepsy and epileptic syndromes 1.0 0.4 Epilepsy, unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 4.2 0.4 0.4 1.2 Meningitis due to other and unspecified causes 1.4 0.4 0.4 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy, unspecified 8.3 13.6 .5 2.9 1.9 Paralpeigi, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 1.5 2.9 1.9 Paralpeigi, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 1.3 1.0 1.9 Paralpeigi, unspecified 1.4 1.5 3.1 1.0 1.9 Malignant neoplasm of brain ACS 9.1 3.1 1.0 1.9	Epilepsy	4.2	40.9	36.9	11.8	18.4
Epile py, unspecified 4.2 40.9 36.9 11.8 18.4 Meningitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 4.2 0.4 0.4 Meningitis, unspecified causes 1.4 0.4 Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy unspecified 8.3 13.6 35 35 35 Hemiplegia, unspecified 1.4 1.5 2.0 1.5 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 6.9 9.1 3.1 0.8 Malignant neoplasm of brain and CNS 9.1 3.1 0.4 1.9 Gongenital hydrocephalus 1.4 0.4 0.4 1.9 Congenital malformations of the nervous system 1.5 1.5 3.8 0.4	Other generalized epilepsy and epileptic syndromes				1.0	0.4
Nearingitis 34.7 22.7 10.8 4.9 16.1 Bacterial meningitis, not elsewhere classified 4.2 1.2 Meningitis due to other and unspecified causes 1.4 1.2 Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy, unspecified 8.3 13.6 3.5 3.5 3.6 3.5 Heminjetis, unspecified 8.3 1.6 4.9 1.9 3.1 9.8 9.2 Paraplegia, unspecified 1.4 1.5 2.0 1.5 1.5 1.9 Paraplegia, unspecified 1.4 1.5 2.0 1.5 1.9 Malignant neoplasm of brain 0.40 3.1 1.0 3.1 9.8 Malignant neoplasm of brain and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of CNS 9.1 3.1 0.4 2.0 2.0 <td< td=""><td>Epilepsy, unspecified</td><td>4.2</td><td>40.9</td><td>36.9</td><td>11.8</td><td>18.4</td></td<>	Epilepsy, unspecified	4.2	40.9	36.9	11.8	18.4
Bacterial meningitis, not elsewhere classified 4.2 1.2 Meningitis, unspecified causes 1.4 0.4 Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy, unspecified 8.3 13.6 3.5	Meningitis	34.7	22.7	10.8	4.9	16.1
Meningitis due to other and unspecified causes 14 0.4 Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy 1.4 0.4 0.4 Cerebral palsy, unspecified 1.4 3.5 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 69 69 69 Malignant and benign neoplasms of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of brain and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 3.8 3.1 Congenital hydrocephalus, unspecified 4.2 1.5 3.8 3.1 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 3.8 Congenital hy	Bacterial meningitis, not elsewhere classified	4.2				1.2
Meningitis, unspecified 29.2 22.7 10.8 4.9 14.6 Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy 1.4 0.4 0.4 Cerebral palsy, unspecified 8.3 13.6 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 2.0 5.0 6.9 6.9 Malignant and benign neoplasm of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of prinal cord, cranial nerves, and other parts of CNS 9.1 3.1 0.4 Congenital maformations of the nervous system 1.5 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 3.8 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 0.4 0.4 Congenital maformation of nervous system, unspecified 1.4 0.4 0.4 Congenital maformation of nervous system, unspecified	Meningitis due to other and unspecified causes	1.4				0.4
Cerebral palsy and other paralytic syndromes 11.1 18.2 3.1 9.8 9.2 Cerebral palsy 1.4 04 3.5 Cerebral palsy, unspecified 8.3 13.6 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 7.7 1.0 3.1 Malignant neoplasm of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of spinal cord, cranial nerveus, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of spinal cord, cranial nerveus system 1.5 0.4 0.4 0.4 Congenital hydrocephalus 1.4 .5 0.4 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 1.5 Spina bifida, unspecified 4.2 1.5 1.2 1.5 1.2 Spina bifida, unspecified (neuropathy NOS) 1.4 0.4 0.4	Meningitis, unspecified	29.2	22.7	10.8	4.9	14.6
Cerebral palsy 1.4 0.4 Cerebral palsy, unspecified 8.3 13.6 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paraplegia, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 3.1 0.0 3.1 Malignant neoplasm of brain 3.1 1.0 1.9 9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 0.4 Congenital malformations of the nervous system 1.5 0.4 0.4 0.4 Congenital hydrocephalus 1.4 0.	Cerebral palsy and other paralytic syndromes	11.1	18.2	3.1	9.8	9.2
Cerebral palsy, unspecified 8.3 13.6 3.5 Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 6.9 9.1 3.1 0.0 8.3 Malignant and benign neoplasm of brain 3.1 1.0 3.1 0.8 1.4 1.5 0.4 Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of spinal cord, cranial nervous system 1.5 0.4 0.8 3.8 0.4 0.8 0.4 0.8 0.8 0.4 0.8 0.4 0.8 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0	Cerebral palsy	1.4				0.4
Hemiplegia, unspecified 4.6 1.5 2.9 1.9 Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 6.9 6.9 3.1 0.8 Malignant and benign neoplasms of brain and CNS 9.1 7.7 1.0 3.1 0.8 Malignant neoplasm of brain and other parts of central nervous system 1.5 0.4 0.4 Congenital matformations of the nervous system 1.5 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 0.4 Spina bifida 1.4 0.4 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 0.4 Spina bifida 1.4 0.4 0.4 0.4 0.4 <td>Cerebral palsy, unspecified</td> <td>8.3</td> <td>13.6</td> <td></td> <td></td> <td>3.5</td>	Cerebral palsy, unspecified	8.3	13.6			3.5
Paraplegia, unspecified 4.6 1.5 2.9 1.9 Paraplegia, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 6.9 9.1 7.7 1.0 3.1 Malignant neoplasm of brain 3.1 0.8 3.1 0.8 Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 3.8 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 0.4 Spina bifida 1.4 0.4 0.4 0.4 Spina bifida 1.4 0.4 0.4 0.4 0.4 Spina bifida, unspecified 4.2 1.5 1.5 3.8 Migraine 1.4 0.4 0.4 0.4 0.4 Spina bifida, unspecified 4.2 1.5 1.5 0.4 Other neurological disorders 4.2 1.0 0.4 0.4 0.4 <t< td=""><td>Hemiplegia, unspecified</td><td></td><td></td><td></td><td>4.9</td><td>1.9</td></t<>	Hemiplegia, unspecified				4.9	1.9
Paralytic syndrome, unspecified 1.4 1.5 2.0 1.5 Intrauterine hypoxia 25.0 6.9 Malignant and benign neoplasms of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of brain 3.1 0.8 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital malformations of the nervous system 1.5 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 3.8 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Congenital hydrocephalus, unspecified 4.2 1.2 1.2 Congenital malformation of nervous system, unspecified 4.2 1.5 1.5 Spina bifida, unspecified 4.2 1.2 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine, unspecified 1.4 1.0 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus <td>Paraplegia, unspecified</td> <td></td> <td>4.6</td> <td>1.5</td> <td>2.9</td> <td>1.9</td>	Paraplegia, unspecified		4.6	1.5	2.9	1.9
Intrauterine hypoxia 25.0 6.9 Malignant and benign neoplasms of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of brain 3.1 0.8 3.1 0.8 Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 0.4 Spina bifida 1.4 0.4 0.4 Spina bifida 1.4 0.4 0.4 Spina bifida 4.2 1.5 1.5 Congenital malformation of nervous system, unspecified 4.2 0.4 0.4 Migraine 4.2 0.4 0.4 0.4 Spina bifida, unspecified (neuropathy NOS) 1.5 1.0 0.4 Migraine, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 Symptoms and signs involvi	Paralytic syndrome, unspecified	1.4		1.5	2.0	1.5
Malignant and benign neoplasms of brain and CNS 9.1 7.7 1.0 3.1 Malignant neoplasm of brain 3.1 0.8 Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital malformations of the nervous system 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida, unspecified 4.2 1.2 0.4 Outgenital malformation of nervous system, unspecified 4.2 1.5 1.5 Spina bifida, unspecified 4.2 0.4 0.4 Other neurological disorders 4.2 0.4 0.4 Migraine, unspecified 1.4 0.4 0.4 Migraine, unspecified (neuropathy NOS) 1.5 1.0 0.4 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous 4.2 1.5 1.5 1.5 Hydrocephalus 4.2 1.5 1.5 1.5 1.5 Symptoms and signs involv	Intrauterine hypoxia	25.0				6.9
Malignant neoplasm of brain 3.1 0.8 Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital malformations of the nervous system 1.5 0.4 Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 0.4 Spina bifida 1.4 0.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 0.4 Spina bifida, unspecified 4.2 1.5 1.5 Congenital malformation of nervous system, unspecified 1.4 0.4 Spina bifida, unspecified 4.2 1.2 0.4 Migraine 1.4 0.4 1.2 0.4 Migraine 1.4 0.4 1.2 0.4 1.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5<	Malignant and benign neoplasms of brain and CNS		9.1	7.7	1.0	3.1
Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS 9.1 3.1 1.0 1.9 Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital malformations of the nervous system 1.5 0.4 Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.5 0.4 Congenital malformation of nervous system, unspecified 4.2 1.5 0.4 Other neurological disorders 4.2 0.4 0.4 0.4 Migraine 1.4 0.4	Malignant neoplasm of brain			3.1		0.8
Benign neoplasm of brain and other parts of central nervous system 1.5 0.4 Congenital malformations of the nervous system 12.5 1.5 3.8 Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.5 1.5 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 0.4 1.4 Other neurological disorders 4.2 0.4 0.4 Migraine 1.4 0.4 0.4 0.4 Nigraine 1.0 0.4 0.4 0.4 Nigraine 3.1 1.0 0.4 Nigraine 3.1 1.0 0.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous 6.9 9.1 6.2 2.9 5.4 end unspecified symptoms and signs involving the nervous and musculoskelet	Malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS		9.1	3.1	1.0	1.9
Congenital malformations of the nervous system 12.5 1.5 3.8 Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine 1.4 0.4 0.4 0.4 0.4 Migraine, unspecified 1.4 0.4 0.4 0.4 0.4 Migraine, unspecified (neuropathy NOS) 1.5 1.0 0.4 0.4 Hydrocephalus 4.2 1.5 1.5 1.5 5 Symptoms and signs involving the nervous and musculoskeletal systems	Benign neoplasm of brain and other parts of central nervous system			1.5		0.4
Congenital hydrocephalus 1.4 0.4 Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine 3.1 1.0 0.4 Migraine, unspecified 3.1 1.0 1.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous 4.2 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.0 0.4 Other and unspecified symptoms and signs involving 1.0 0.4 0.4 the nervous and musculoskeletal systems 6.9 9	Congenital malformations of the nervous system	12.5		1.5		3.8
Congenital hydrocephalus, unspecified 4.2 1.5 1.5 Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 0.4 Migraine 1.4 0.4 Migraine, unspecified 1.4 0.4 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.4 Hydrocephalus 4.2 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous 6.9 9.1 6.2 2.9 5.4 and musculoskeletal systems 1.0 0.4 0.4 0.4 0.4 0.4 the nervous and musculoskeletal systems 6.9 9.1 6.2 2.0 2.3 Other and unspecified convuls	Congenital hydrocephalus	1.4				0.4
Spina bifida 1.4 0.4 Spina bifida, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine 1.0 0.4 Migraine, unspecified 1.0 0.4 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous and musculoskeletal systems 6.9 9.1 6.2 2.9 5.4 other nervous and musculoskeletal systems 1.0 0.4 0.4 0.4 We nervous and musculoskeletal systems 1.0 0.4 0.4 0.4 Headache 6.9 9.1 6.2 2.0 2.3 Other and unspecified convulsions 6.9 9.1 2.7 2.2 65 102 261	Congenital hydrocephalus, unspecified	4.2		1.5		1.5
Spina bifida, unspecified 4.2 1.2 Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine 1.0 0.4 Migraine, unspecified 3.1 1.0 1.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous and musculoskeletal systems 6.9 9.1 6.2 2.9 5.4 Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems 1.0 0.4 0.4 Other and unspecified convulsions 6.9 9.1 6.2 2.9 5.4 Migraine 1.0 0.4 0.4 0.4 0.4 Headache 6.9 9.1 6.2 2.0 2.3 Other and unspecified convulsions 6.9 9.1 2.7 2.7 Number of deaths 72 22 65 102 261	Spina bifida	1.4				0.4
Congenital malformation of nervous system, unspecified 1.4 0.4 Other neurological disorders 4.2 6.2 2.9 3.8 Migraine 1.0 0.4 Migraine, unspecified 3.1 1.0 1.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.0 0.8 Symptoms and signs involving the nervous and musculoskeletal systems 6.9 9.1 6.2 2.9 5.4 Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems 1.0 0.4 Other and unspecified convulsions 6.9 9.1 6.2 2.9 5.4 Migraine 1.0 0.4 0.4 0.4 0.4 Migraine, unspecified symptoms and signs involving the nervous and musculoskeletal systems 1.0 0.4 Other and unspecified convulsions 6.9 9.1 2.7 Number of deaths 72 22 65 102 261	Spina bifida, unspecified	4.2				1.2
Other neurological disorders4.26.22.93.8Migraine1.00.4Migraine, unspecified3.11.01.2Polyneuropathy, unspecified (neuropathy NOS)1.51.00.8Hydrocephalus4.21.51.5Symptoms and signs involving the nervous and unspecified systems6.99.16.22.95.4Other and unspecified systems1.00.41.00.4Headache6.22.02.32.7Number of deaths722265102261	Congenital malformation of nervous system, unspecified	1.4				0.4
Migraine 1.0 0.4 Migraine, unspecified 3.1 1.0 1.2 Polyneuropathy, unspecified (neuropathy NOS) 1.5 1.0 0.8 Hydrocephalus 4.2 1.5 1.5 1.5 Symptoms and signs involving the nervous and musculoskeletal systems 6.9 9.1 6.2 2.9 5.4 Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems 1.0 0.4 0.4 Headache 6.2 2.0 2.3 2.7 2.7 2.7 Number of deaths 72 22 65 102 261	Other neurological disorders	4.2		6.2	2.9	3.8
Migraine, unspecified3.11.01.2Polyneuropathy, unspecified (neuropathy NOS)1.51.00.8Hydrocephalus4.21.51.5Symptoms and signs involving the nervous and musculoskeletal systems6.99.16.22.95.4Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems1.00.4Headache6.22.02.3Other and unspecified convulsions6.99.12.7Number of deaths722265102261	Migraine				1.0	0.4
Polyneuropathy, unspecified (neuropathy NOS)1.51.00.8Hydrocephalus4.21.51.5Symptoms and signs involving the nervous and musculoskeletal systems6.99.16.22.95.4Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems1.00.4Headache6.22.02.3Other and unspecified convulsions6.99.12.7Number of deaths722265102261	Migraine, unspecified			3.1	1.0	1.2
Hydrocephalus4.21.51.5Symptoms and signs involving the nervous and musculoskeletal systems6.99.16.22.95.4Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems1.00.4Headache Other and unspecified convulsions6.99.12.7Number of deaths722265102261	Polyneuropathy, unspecified (neuropathy NOS)			1.5	1.0	0.8
Symptoms and signs involving the nervous and musculoskeletal systems6.99.16.22.95.4Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems1.00.4Headache6.22.02.3Other and unspecified convulsions6.99.12.7Number of deaths722265102261	Hydrocephalus	4.2		1.5		1.5
and musculoskeletal systemsOther and unspecified symptoms and signs involving1.00.4the nervous and musculoskeletal systems6.22.02.3Headache6.99.12.7Number of deaths722265102261	Symptoms and signs involving the nervous	6.9	9.1	6.2	2.9	5.4
Other and unspecified symptoms and signs involving1.00.4the nervous and musculoskeletal systems6.22.02.3Headache6.99.12.7Other and unspecified convulsions6.99.12.7Number of deaths722265102261	and musculoskeletal systems					
the nervous and musculoskeletal systems 6.2 2.0 2.3 Headache 6.9 9.1 2.7 Number of deaths 72 22 65 102 261	Other and unspecified symptoms and signs involving				1.0	0.4
Headache 6.2 2.0 2.3 Other and unspecified convulsions 6.9 9.1 2.7 Number of deaths 72 22 65 102 261	the nervous and musculoskeletal systems					
Other and unspecified convulsions 6.9 9.1 2.7 Number of deaths 72 22 65 102 261	Headache			6.2	2.0	2.3
Number of deaths 72 22 65 102 261	Other and unspecified convulsions	6.9	9.1			2.7
	Number of deaths	72	22	65	102	261

Table 2 Cause-specific mortality fraction (%) estimates of neurological disorders and enilensy by sex age residency and zone					
\mathbf{U}	Table 2. Cause-specific mortal	ity fraction (%) estimates	of neurological disorders	and epilepsy by sex, age	e, residency, and zone.

	Neurological disorders			Epilepsy			
	Deaths	CSMF (95% CI)	MRF (95% CI)	Deaths	CSMF (95% CI)	MRF (95% CI)	
Sex							
Males	134	4.76 (4-5.55)	0.90 (0.70-1.16)	36	1.28 (0.86-1.69)	2.37 (1.23-4.88)	
Females	127	5.27 (4.38-6.16)		13	0.54 (0.25-0.83)		
Age							
<5	72	4.13 (3.19–5.06)	0.71 (0.52-0.97)	3	0.17 (0-0.37)	0.23 (0.04-0.84)	
5–19	22	6.25 (3.72-8.78)	1.07 (0.64–1.71)	9	2.56 (0.91-4.20)	3.45 (1.30-8.72)	
20–49	65	4.72 (3.6-5.84)	0.81 (0.58-1.12)	24	1.74 (1.05-2.43)	2.35 (1.15-5.03)	
50+	102	5.82 (4.72-6.91)		13	0.74 (0.34-1.14)		
Residency							
Rural	149	5.63 (4.75-6.50)		30	1.13 (0.73–1.54)	0.65 (0.35-1.19)	
Urban	112	4.35 (3.56-5.13)	0.77 (0.60-0.99)	19	0.74 (0.41-1.07)		
Zone							
Western	31	4.74 (3.11-6.37)	0.75 (0.46-1.21)	7	1.07 (0.28-1.86)	1.00 (0.31-3.16)	
Northern	25	3.53 (2.17-4.88)	0.56 (0.33-0.93)	3	0.42 (0-0.90)	0.40 (0.07-1.65)	
Central	43	4.68 (3.31-6.04)	0.74 (0.48-1.15)	12	1.30 (0.57-2.04)	1.22 (0.46-3.45)	
Southern Highlands	39	6.61 (4.60-8.61)	1.05 (0.67-1.64)	4	0.68 (0.01-1.34)	0.63 (0.14-2.37)	
Eastern	43	4.8 (3.41-6.21)	0.77 (0.49-1.18)	8	0.89 (0.28-1.51)	0.84 (0.27-2.56)	
Southern	33	4.65 (3.10-6.20)	0.74 (0.46-1.18)	7	0.99 (0.26-1.71)	0.92 (0.28-2.91)	
Lake	47	6.27 (4.54-8.01)		8	1.07 (0.33-1.80)		
Overall	261	4.99 (4.40–5.58)		49	0.94 (0.68–1.20)		

Ref: Reference category; CSMF: cause-specific mortality fraction, MRF, mortality rate fraction; CI: confidence interval.

epilepsy and unspecified epileptic syndromes (2.0%) were the category reported for all deaths.

Of 5225 certified deaths, 49 were epilepsy-related with a CSMF of epilepsy of 0.94% (95% CI:

0.68–1.20) with significantly higher estimates in males (1.28%) than females (0.54%) (MRF = 2.37, 95% CI: 1.23–4.88) (Table 3). Epilepsy mortality was higher in children aged 5–19 (MRF = 3.45, 95% CI:

	Cerebrovascular diseases			Cerebrovascular diseases (50+ years)		
	Deaths	CSMF (95% CI)	MRF (95% CI)	Deaths	CSMF (95% CI)	MRF (95% CI)
Sex						
Males	38	1.99 (1.43-2.55)		27	2.87 (1.80-3.93)	0.58 (0.34-0.97)
Females	48	1.35 (0.92-1.78)	0.68 (0.43-1.06)	40	4.93 (3.44-6.42)	
Age						
<5	1	0.06 (0.00-0.17)	0.02 (0.00-0.09)			
5–19	0					
20–49	18	1.31 (0.71–1.91)	0.34 (0.19-0.58)			
50+	67	3.82 (2.92-4.72)				
Residency						
Rural	35	1.32 (0.89–1.76)		29	3.42 (2.20-4.65)	
Urban	51	1.98 (1.44–2.52)	1.50 (0.95-2.37)	38	4.19 (2.89-5.50)	1.23 (0.73-2.06)
Zone						
Western	11	2.14 (1.10-3.17)	0.79 (0.33-1.81)	9	6.08 (2.23-9.93)	0.99 (0.37-2.47)
Northern	9	1.27 (0.44-2.09)	0.59 (0.23-1.43)	7	2.30 (0.62-3.99)	0.37 (0.12-1.00)
Central	8	0.87 (0.27-1.47)	0.41 (0.15-1.01)	6	1.68 (0.35-3.01)	0.27 (0.08-0.76)
Southern Highlands	12	2.03 (0.89-3.17)	0.95 (0.41-2.14)	10	6.54 (2.62-10.45)	1.05 (0.41-2.59)
Eastern	18	2.01 (1.09-2.93)	0.94 (0.45-1.98)	12	3.87 (1.72-6.02)	0.62 (0.26-1.48)
Southern	12	1.69 (0.74-2.64)	0.79 (0.34-1.78)	10	3.68 (1.44-5.91)	0.59 (0.23-1.46)
Lake	16	1.68 (0.70-2.67)		13	6.22 (2.94-9.49)	
Overall	86	1.64 (1.30–1.99)		67	3.82 (2.92-4.72)	

Table 3. Cause-specific mortality fraction (%) estimates of cerebrovascular disorders (95% CI) by sex, age, residency, and zone.

Ref: Reference category; CSMF: cause-specific mortality fraction; MRF: mortality rate fraction; CI: confidence interval.

1.30–8.72) and adults aged 20–49 (MRF = 2.35, 95% CI: 1.15–5.03) than adults aged 50 years and above. Epilepsy mortality was observed to be comparable in urban (0.74%) and rural (1.13%) areas (MRF = 0.65, 95% CI: 0.35–1.19). Epilepsy mortality was also comparable across zones.

Meningitis mortality

Bacterial meningitis accounted for 16.1% of all ND deaths; 34.7% among children < 5 years, 22.7% among children aged 5–19, 10.8% among adults aged 20–49, and 4.9% among adults older than 50 years (Table 1). No viral-related meningitis deaths were identified by physicians.

Of certified deaths, meningitis-related mortality was estimated with a CSMF of 0.80% (95% CI: 0.56–1.04) (Table 4). Compared to adults older than 50 years (CSMF = 0.28%), meningitis mortality was high in children 0–4 (1.43%) (MRF = 5.02, 95% CI: 1.89–16.81) and those aged 5–19 years (1.42%) (CSMF = 4.98, 95% CI: 1.15–21.64). Meningitis mortality was comparable in urban (0.66%) and rural (0.94%) (MRF = 0.70, 95% CI: 0.35–1.35) areas and among males (1.04%) and females (0.79%) (MRF = 1.04, 95% CI: 0.54–2.04).

Subanalysis of meningitis mortality in children similar to the above indicated no differences in CSMF related to sex, age, residency, and zone.

Cerebral palsy and other paralytic syndromes

CP accounted for 9.2% of all ND deaths; 11.1% among children < 5 years, 18.2% among children aged 5–19, 3.1% among adults aged 20–49, and 9.8% among adults older than 50 years (Table 1). Cerebral palsy deaths were reported in children younger than 20 years while paralytic syndromes (hemiplegia, paraplegia, and paralysis) were common in adults older than 20 years. A total of 24 deaths from CP and other paralytic syndromes were identified with a CSMF of 0.46% (95% CI: 0.27–0.65). Mortality of cerebral palsy in children younger than 5 years was estimated with a CSMF of 0.40% (95% CI: 0.10–0.70).

Intrauterine hypoxia

A total of 18 deaths from IH were coded. IH accounted for 6.9% of all ND deaths and 25.0% among children younger than 5 years died of ND. Given the fact that IH is diagnosed at birth or the early days of neonatal life, mortality associated with IH in neonates was estimated with a CSMF of 2.06% (95% CI: 1.12–3.01).

The remaining ND-related deaths were broadly grouped as malignant and benign neoplasms of the brain and CNS, congenital malformations of the nervous system, other neurological disorders, and symptoms and signs involving the nervous and musculoskeletal systems. The mortality of these ND combined were estimated with a CSMF of 0.80% (95% CI: 0.56-1.04). Malignant and benign neoplasms of the brain and CNS were reported and estimated in individuals aged < 5 years with a CSMF of 0.23% (95% CI: 0.07-0.39). Congenital malformations of the nervous system were reported and estimated in children < 5 years with a CSMF of 0.52% (95% CI: 0.18-0.85).

Discussion

This study provides the first detailed analysis of national data on neurological disorders in Tanzania. The study utilized a SAVVY approach developed to provide a standardized methodology in generating mortality

Table 4. Cause-specific mortality fraction (%) estimates of meningitis disorders by sex, age, residency, and zone.

	Meningitis			Meningitis (age 0–19)		
	Deaths	CSMF(95% CI)	MRF (95% CI)	Deaths	CSMF (95% CI)	MRF (95% CI)
Sex						
Males	23	0.82 (0.48-1.15)	1.04 (0.54-2.04)	18	1.57 (0.85-2.29)	1.25 (0.57–2.84)
Females	19	0.79 (0.43-1.14)		12	1.26 (0.55–1.97)	
Age						
<5	25	1.43 (0.88-1.99)	5.02 (1.89-16.81)		1.43 (0.88–1.99)	1.01 (0.38–3.37)
5–19	5	1.42 (0.18-2.66)	4.98 (1.15-21.64)	25	1.42 (0.18-2.66)	
20–49	7	0.51 (0.13-0.88)	1.78 (0.49–7.13)	5		
50+	5	0.28 (0.03-0.53)				
Residency						
Rural	25	0.94 (0.57-1.31)		19	1.57 (0.87-2.27)	
Urban	17	0.66 (0.35-0.97)	0.70 (0.35-1.35)	11	1.24 (0.51–1.97)	0.79 (0.34–1.75)
Zone						
Western	5	0.76 (0.10-1.43)	0.67 (0.17-2.11)	5	1.26 (0.16-2.37)	0.58 (0.15-2.01)
Northern	4	0.56 (0.01-1.11)	0.47 (0.10-1.68)	1	0.56 (0.00-1.65)	0.25 (0.01-1.91)
Central	1	0.11 (0.00-0.32)	0.09 (0.00-0.65)	0		
Southern Highlands	14	2.37 (1.14-3.60)	1.97 (0.80-5.17)	12	4.33 (1.93-6.73)	0.04 (0.02-0.03)
Eastern	5	0.56 (0.07-1.05)	0.46 (0.12-1.55)	1	0.31 (0.00-0.91)	0.14 (0.00-1.05)
Southern	4	0.56 (0.01-1.11)	0.47 (0.10-1.68)	3	1.39 (0.00-2.95)	0.64 (0.11-2.65)
Lake	9	1.20 (0.42-1.98)		8	2.18 (0.69-3.68)	
Overall	42	0.80 (0.56–1.04)		30	1.43 (0.92–1.94)	

Ref: Reference category; CSMF: cause-specific mortality fraction; MRF: mortality rate fraction; CI: confidence interval.

estimates, causes of death and disease classification needed for local, regional and international comparability of mortality statistics. The adopted approach, which included national random samples of enumeration areas provided by the National Bureau of Statistics (NBS), multistage sampling methodology, use of two independent causes-of-death certifiers and ICD-10 guarantee credibility of the study's findings.

The main neurological disorders identified were cerebrovascular diseases, epilepsy, meningitis, cerebral palsy and other paralytic syndromes, and intrauterine hypoxia. Cerebrovascular disorders were the leading cause of death, most of which were attributed to stroke. We estimated that the number of neurological deaths in Tanzania ranged from 18,000 to 22,000 in 2012.

Cerebrovascular diseases

Hypertensive diseases are the major risk factor for ND, specifically stroke and dementia [29]. The STEPwise approach to Surveillance (STEPS) survey designed by WHO estimated high blood pressure (>140/90 mmHg) in 25.9% of adults aged 25-64 years in Tanzania in 2012 [30]. High mortality estimates attributed to hypertension and cerebrovascular disorder observed in SAVVY are incoherent with the prevalence of hypertension reported in STEPS survey. A recent hospital mortality study for Tanzania mainland reported an increase of stroke-related mortality to 27% between 2006-2010 and 2011-2015. In the study period from 2006 to 2015, deaths attributable to stroke were 3.1% while cardiorespiratory and cardio-circulatory diseases accounted for 6.6% and 5.6%, respectively [31]. Comparable estimates of cerebrovascular mortality by residency in this study indicate lifestyle-related diseases equally affect rural and urban residents. These observations deviate from the common knowledge that urban residents are at higher

risk for NCD in general compared to rural residents. Insufficient coverage of human resources and medicine supply for cardiovascular diseases may also explain why Tanzania lags behind in slowing down the increasing trends in the majority of NCD. In 2014, the Tanzania Service Provision Assessment Survey (TSPA) indicated a lack of guidelines for healthcare providers for NCD services [32]. The TSPA indicated that less than 10% of facilities have providers who have recently received training in providing services for cardiovascular and other chronic diseases [32]. Despite the fact that majority of Tanzanians access their health services through dispensaries and health facilities, the TSPA indicated the that availability of essential medicines for cardiovascular and other chronic diseases is lower in most dispensaries and health facilities than in hospitals.

Epilepsy

The population estimate of 7.3 (95% CI: 6.9-7.6) deaths per 100,000 was comparable to estimates in the three large demographic surveillance sites: 5.4 (95% CI: 4-6.7) in Rufiji, 7.9 (95% CI: 6.1-9.7) in Ifakara Rural and 3.9 (95% CI: 1.3-6.4) deaths per 100,000 population in Ifakara Urban [33]. Epilepsy mortality rate and CSMF were comparable to estimates reported elsewhere in most developing countries. The majority of interventions targeting epilepsy are those aimed at eliminating the Taenia solium tapeworm, which is responsible for the development of taeniosis, a major cause of preventable epilepsy [34,35]. In Tanzania, the National Schistosomiasis Control Program (NSCP) routinely implemented school-based mass drug administration targeting both schistosomiasis and Taenia solium [36]. Several interventions have been devised to reduce parasite infections in Tanzania; however, most of these

interventions have proved to yield modest efficacy, and therefore need to be re-evaluated [37].

Despite these efforts, mortality of epilepsy has remained stable over the years in Tanzania with reference to the previous national demographic surveillance system's study conducted in 1992–1995, which estimated an epilepsy mortality rate of 15 and 5 deaths per 100,000 population in males and females, respectively [38].

Probable contributors to stagnation in reduction of epilepsy mortality include the rise of cerebrovascular diseases attributed to epilepsy such as stroke, the increase in emerging infectious diseases such as HIV, and an increase in traumatic brain injuries as a result of wide use of bikes/motor bikes without a helmet and vehicles without a seatbelt. These factors probably explain why in this study we have more mortality due to epilepsy in adults than in children, who normally have more epilepsy in general in SSA, especially those originating from febrile seizures.

Meningitis

The mortality of meningitis was low, accounting for less than <0.8% of all deaths and 1.5% in children aged younger than 5 years. Analysis of WHO-reported cases of meningitis in Africa identified 11 regions (the 'meningitis belt') that account for 90% of all meningitis in SSA (Tanzania not included) [39]. High meningitis mortality in children may be explained by the fact that the meningitis pathogen that accounts for most cases of acute bacterial meningitis affects neonates and children. Observed meningitis deaths in adults may mostly constitute AIDS or TB-related deaths based on the fact that meningitis (cryptococcal) is a leading cause of death among HIV-infected individuals in SSA and in the studied population, where the latest HIV prevalence was estimated in adults aged 15-49. However, the unexpected low mortality of meningitis in adults may be explained by the fact that meningitis may be reported as immediate but not the underlying cause of death. The analysis in this study focused on underlying causes of death.

Cerebral palsy and other paralytic syndromes

Cerebral palsy is a lifelong disability in children of non-progressive brain damage which most likely occurred during the antenatal, perinatal, or early postnatal period. Clinical presentations include challenges in coordination, stiff and/or weak muscles, tremors, and in some cases problem s in sense organs and reasoning. The burden of CP in Africa is estimated at 2–2.5 cases per 1000 live births and globally affects 0.2% of neonates [40,41]. Improving care at birth may have potential in reducing perinatal adverse events that are likely to result in the development of this disorder. There are scarce data on mortality in cerebral palsy in Africa, hence this study provides valuable statistics for future studies of the disorder.

Mortality from paralytic syndromes (including hemiplegia and paraplegia) was more common in individuals older than 50 years. These disorders may be sequelae of stroke, degenerative diseases, or infection of the nervous system; therefore, further investigation of its epidemiology is needed.

Intrauterine hypoxia

In general, IH is the form of birth asphyxia that affects the brain as a result of oxygen deprivation of the fetus [42]. Birth asphyxia is a more general term, and we anticipate that most clinicians would classify IH as birth asphyxia. Despite the possibility for misclassification, physicians were able to capture IH deaths, which were the second leading cause of neurological death in children under 5 years. Poor maternal health condition, fetus development, and adverse perinatal events are the major culprits for the development of these disorders [42]. Improving antenatal and care at birth by scaling-up facility delivery and improving basic and comprehensive emergency obstetric and newborn care may significantly reduce pregnancy- or birth-related neurological morbidities such as cerebral palsy and mortality.

Comparison with modeled estimates

Our estimates were lower or higher than those reported by GBD reports (Table 5) [43]. The estimated CSMFs of cerebrovascular diseases were comparable to estimates from the GBD for adults aged 15–49 years and close to estimates for all ages.

Table 5. Cause-specific mortality fraction (%) comparison of neurological disorders by study.

	Age 0–4 years		Age 15-	-49 years	All ages		
	SAVVY	GBD	SAVVY	GBD	SAVVY	GBD	
Cerebrovascular	0.02 (0.00-0.09)	0.07 (0.04-0.09)	1.20 (0.65–1.92)	1.23 (0.96–1.76)	1.64 (1.30–1.99)	3.16 (2.66-3.63)	
Epilepsy	0.17 (0-0.37)	0.11 (0.08-0.14)	1.94 (1.24–2.64)	0.55 (0.43-0.69)	0.94 (0.68-1.20)	0.25 (0.22-0.30)	
Meningitis	1.43 (0.88–1.99)	3.53 (2.30-6.07)	0.53 (0.16-0.91)	1.53 (1.06–2.23)	0.80 (0.56-1.04)	2.10 (1.61–2.94)	
Road injuries	0.28 (0.04–0.54)	0.54 (0.36–0.84)	5.83 (4.64-7.01)	2.41 (1.89–2.99)	2.43 (2.01–2.84)	1.48 (1.29–1.67)	

Legend:

Data sources

SAVVY: Analysis of Sample vital registration with verbal autopsy

GBD: Extracted from Global Burden of Disease report

SAVVY estimates of deaths attributable to epilepsy and road traffic injuries were higher in all age categories and overall than those reported in the GBD. On the other hand, the GBD reported higher estimates for deaths attributable to meningitis. The observed differences may be linked to methodological limitations in both approaches; however, SAVVY estimates are more likely to be closer to true population estimates. A substantial proportion of data used in generating the GBD for Tanzania are those derived from health and demographic surveillance systems, most of which are located in poor rural areas [44,45]. Recently, the 2017 GBD report in Tanzania compiled cerebrovascular diseasesdata dated from 2010 to 1993 due to the limited number of studies and poor coverage of civil and vital registration systems [46].

Limitations

Missing and misclassifying neurological disorders was the main possible limitation of this study attributed to lack of clinical training in neurology among physicians conducting death certification. A substantial proportion of deaths were coded as malaria in this study; however, some of the clinical manifestations of cerebral malaria such as fever, vomiting, and convulsions are also clinical manifestations of neurological disorders such as meningitis and epilepsy. Other possible misclassifications include those related to misclassifying cerebrovascular disorder as hypertensive disease, or vice versa. We did not observe traumatic brain injuries or intracranial deaths in this study despite the high mortality of road injuries estimated at 2.4% in all ages and 5.8% (95% CI: 4.7-7.1) in adults aged 15-49 years (results not reported but provided for contextual reasoning). Road injuries are one of the main causes of brain injuries; therefore, lack of information from VA or medical records may have resulted in missing some traumatic brain injury deaths in this study [9,10,47]. With regards to comparability of this study across countries, regions, and internationally, adoptions of newer versions of ICD-10 and the tabulation list of neurological disorders are likely to result in different mortality estimates elsewhere [48]. The recent version of ICD-10 recommends grouping some hypertensive disorders as cerebrovascular deaths; such changes are likely to result in estimates that are incomparable to what was observed in this study [49].

Conclusions

The SAVVY survey provided estimates mortality burden of neurological disorders in Tanzania to the level of zones. Cerebrovascular diseases, epilepsy, meningitis, cerebral palsy and other paralytic syndromes, and intrauterine hypoxia are the leading causes of neurological mortality in Tanzania. The SAVVY sampling design strengthens the study in terms of representativeness for the nation and reliability of cause-of-death determination, and provides national baseline data on epidemiological information on neurological disorders needed for prevention and intervention programs. These estimates are rare in most SSA; therefore, we believe our archived data sets will contribute to advancing knowledge of neurological disorders. On the other hand, the burden associated with morbidities of neurological disorders might be far higher than that of mortality. In the case of stroke, mortality rates and deaths have substantially declined in most countries; however, the number of people living with stroke-related disabilities has been increasing. Reliable morbidity data can only be obtained when there is routine healthcare services data of good quality and community-based surveys. Integrating measures of morbidities such as DALYs in SAVVY design may provide a complete picture of disease, social and economic burden not only of neurological disorders but also of other prevalent diseases.

Acknowledgments

We acknowledge the valuable contribution of residents in selected enumeration areas for their participation in the SAVVY study. We appreciate the efforts of the key informants and verbal autopsy coordinators who identified deaths and conducted the VA interviews, respectively. We are grateful for the managers and the entire team for logistic arrangements and data management activities.

Author contributions

FL analyzed data and draftrd the initial manuscript. HM designed the study. HM, CN, and PO interpreted results, revised the manuscript, and supervised the study.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics and consent

The study protocol was approved by Ifakara Health Institution Internal Review Board, National Institute of Health Research and Commission of Science and Technology, Tanzania (Clearance reference letter No. NIMR/HQ/R.8a/Vol. IX/1256). All participants were enrolled through verbal consent.

Funding information

The SAVVY work was funded by Center for Disease Control Prevention (CDC), Global Fund, and the Ifakara Health Institute core resources; with support from the governments of the UK; Switzerland; Norway; and Ireland. Training and data analysis funding were provided by City and Canton of Basel, Switzerland, and Training Unit of Ifakara Health Institute Tanzania.

Paper context

In the context of low- and middle-income countries, it has been established that the majority of neurological disorders are linked to infections and brain injuries. However, in the context of epidemiological transition, we hypothesize that there is high emerging incidence of age-related neurological disorders such as dementia, cerebrovascular and heart diseases. We utilize a SAVVY study; a national representative sample and explore mortality of neurological disorders in Tanzania by sex, residence, and special geographic areas (zone).

References

- Mackenbach JP, Karanikolos M, Looman CW. The rise of mortality from mental and neurological diseases in Europe, 1979–2009: observational study. BMC Public Health. 2014;14:840.
- [2] Pritchard C, Rosenorn-Lanng E, Silk A, et al. Controlled population-based comparative study of USA and international adult [55–74] neurological deaths 1989–2014. Acta Neurol Scand. 2017;136:698–707.
- [3] Chin JH, Vora N. The global burden of neurologic diseases. Neurology. 2014;83:349–351.
- [4] Birbeck GL. Neurologic disease in a rural Zambian hospital. Trop Doct. 2001;31:82–85.
- [5] Winkler AS, Friedrich K, König R, et al. The head nodding syndrome-clinical classification and possible causes. Epilepsia. 2008;49:2008–2015.
- [6] Winkler AS, Blocher J, Auer H, et al. Anticysticercal and antitoxocaral antibodies in people with epilepsy in rural Tanzania. Trans R Soc Trop Med Hyg. 2008;102:1032–1038.
- [7] Winkler AS, Blocher J, Auer H, et al. Epilepsy and neurocysticercosis in rural Tanzania-an imaging study. Epilepsia. 2009;50:987–993.
- [8] Howlett WP. Neurology in Africa. Neurology. 2014;83:654–655.
- [9] Winkler AS, Mosser P, Schmutzhard E. Neurological disorders in rural Africa: a systematic approach. Trop Doct. 2009;39:102–104.
- [10] Smart, LR, Mangat HS, Issarow B, et al. Severe traumatic brain injury at a tertiary referral center in Tanzania: epidemiology and adherence to brain trauma foundation guidelines. World Neurosurg; 2017;105:238–248.
- [11] Murray CJL, Vos T, Lozano R, et al. Disabilityadjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–2223.
- [12] Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiology. 2015;45:161–176.
- [13] Baxter AJ, Charlson FJ, Cheng HG, et al. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3:832–841.
- [14] AbouZahr C, Boerma T, Hogan D. Global estimates of country health indicators: useful,

unnecessary, inevitable? Glob Health Action. 2017;10:1290370.

- [15] Dalal S, Beunza JJ, Volmink J, et al. Noncommunicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol. 2011;40:885–901.
- [16] Dewhurst F, Dewhurst MJ, Orega G, et al. Neurological disorder screening in the elderly in low-income countries. J Neurol. 2012;259:2189–2197.
- [17] Pakpoor J, Goldacre M. Neuroepidemiology: the increasing burden of mortality from neurological diseases. Nat Rev Neurol. 2017;13:518–519.
- [18] Phillips DE, AbouZahr C, Lopez AD, et al. Are well functioning civil registration and vital statistics systems associated with better health outcomes? Lancet. 2015;386:1386-1394.
- [19] MEASURE Evaluation. SAVVY: sample vital registration with verbal autopsy. 2018 [cited 2018]. Available from: https://www.measureevaluation.org/resources/ tools/health-information-systems/savvy
- [20] Mikkelsen L, Phillips DE, AbouZahr C, et al. A global assessment of civil registration and vital statistics systems: monitoring data quality and progress. Lancet. 2015;386:1395–1406.
- [21] Sankoh O, Byass P. Time for civil registration with verbal autopsy. Lancet Glob Health. 2014;2:e693–e694.
- [22] Setel PW, Whiting DR, Hemed Y, et al. Validity of verbal autopsy procedures for determining cause of death in Tanzania. Trop Med Int Health. 2006;11:681–696.
- [23] Kabadi GS, Geubbels E, Lyatuu I, et al. Data resource profile: the sentinel panel of districts: tanzania's national platform for health impact evaluation. Int J Epidemiol. 2015;44:79–86.
- [24] World Health Organization. Verbal autopsy standards: ascertaining and attributing causes of death. 2007 [cited 2018]. Available from: http://www.who. int/healthinfo/statistics/verbalautopsystandards/en/ index3.html
- [25] World Health Organization. ICD-10 : international statistical classification of diseases and related health problems (Tenth revision, 2nd ed.) World Health Organization; 2004. http://www.who.int/iris/handle/ 10665/42980.
- [26] Jette N, Beghi E, Hesdorffer D, et al. ICD coding for epilepsy: past, present, and future-a report by the international league against epilepsy task force on ICD codes in epilepsy. Epilepsia. 2015;56:348-355.
- [27] Roth GA, Johnson CO, Nguyen G, et al. Methods for estimating the global burden of cerebrovascular diseases. Neuroepidemiology. 2015;45:146–151.
- [28] Kumalija CJ, Perera S, Masanja H, et al. Regional differences in intervention coverage and health system strength in Tanzania. PLoS One. 2015;10:e0142066.
- [29] Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008;7:476-484.
- [30] Mayige M, Kagaruki G. Tanzania steps survey report. Dar es salaam: Ministry of Health and Social Welfare and Nationalinstitute for Medical Research in Collaboration with World Health Organisation; 2013.
- [31] Mboera, LEG, Rumisha SF, Kumalija CJ, et al. Hospital mortality patterns and causes of death in Tanzania, 2006–2015. Dar es Salaam (Tanzania): National Institute for Medical Research, Dar es Salaam, Tanzania and Ministry of Health, Community Development, Gender, Elderly and Children; 2007.
- [32] Ministry of Health and Social Welfare (MoHSW) [Tanzania Mainland], M.o.H.M.Z., National Bureau

of Statistics (NBS), Office of the Chief Government Statistician (OCGS), and ICF International. Tanzania service provision assessment survey (TSPA) 2014–15. Dar es Salaam (Tanzania): MoHSW, MoH, NBS, OCGS, and ICF International; 2015.

- [33] Levira F, Odermatt P, Newton CR, et al. Secular trends in neurological disorders mortality in Tanzania: analysis of data from health demographic surveillance sites in Tanzania. 2018 (Unpublished).
- [34] Blocher J, Schmutzhard E, and Gotwald T, et al. Epilepsy and neurocysticercosis in northern Tanzania. Trop Med Int Health. 2007;12:90.
- [35] Blocher J, Schmutzhard E, Wilkins PP, et al. A cross-sectional study of people with epilepsy and neurocysticercosis in Tanzania: clinical characteristics and diagnostic approaches. PLoS Negl Trop Dis. 2011;5(6): e1185.
- [36] Braae UC, Magnussen P, Harrison W, et al. Effect of the national schistosomiasis control program on taenia solium taeniosis and porcine cysticercosis in rural communities of Tanzania. Am J Trop Med Hyg. 2017;95:378–379.
- [37] Mwidunda SA, Carabin H, Matuja WBM, et al. A school based cluster randomised health education intervention trial for improving knowledge and attitudes related to Taenia solium cysticercosis and taeniasis in Mbulu district, northern Tanzania. PLoS One. 2015;10:e0118541.
- [38] Aspray TJ. The use of verbal autopsy in attributing cause of death from epilepsy. Epilepsia. 2005;46:15–17.
- [39] Zhao S, Lin Q, He D, et al. Meningitis epidemics shift in sub-Saharan belt. Int J Infect Dis. 2018;68:79–82.
- [40] Donald KA, Samia P, Kakooza-Mwesige A, et al. Pediatric cerebral palsy in Africa: a systematic review. Semin Pediatr Neurol. 2014;21:30–35.

- [41] Graham HK, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nat Rev Dis Primers. 2016;2:15082.
- [42] Hutter D, Kingdom J, Jaeggi E. Causes and mechanisms of intrauterine hypoxia and its impact on the fetal cardiovascular system: a review. Int J Pediatr. 2010;2010:401323.
- [43] IHME. Global burden of disease (GBD). Seattle, USA: Institute of Health Metrics and Evaluation. 2016.
- [44] Mrema S, Kante AM, Levira F, et al. Health & demographic surveillance system profile: the Rufiji health and demographic surveillance system (Rufiji HDSS). Int J Epidemiol. 2015;44:472–483.
- [45] Geubbels E, Amri S, Levira F, et al. Health & demographic surveillance system profile: the Ifakara rural and urban health and demographic surveillance system (Ifakara HDSS). Int J Epidemiol. 2015;44:848-861.
- [46] Institute for Health Metrics and Evaluation. Global burden of disease study 2016 (GBD 2016) data input sources tool. 2018. Available from: http://ghdx.health data.org/gbd-2016/data-input-sources?locations= 189&components=3&causes=494
- [47] Okeng'o K, Chillo P, Gray WK, et al. Early mortality and associated factors among patients with stroke admitted to a large teaching hospital in Tanzania. J Stroke Cerebrovasc Dis. 2017;26:871–878.
- [48] Mathers CD, Fat DM, Inoue M, et al. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83:171–177.
- [49] ICD10 Data. Cerebrovascular diseases I60-I69. 2018. Available from: http://www.icd10data.com/ ICD10CM/Codes/I00-I99/I60-I69